Search for a trial

Patient information combined for local therapy outcome assessment in breast cancer-longitudinal

In breast-conserving surgery, there is evidence that approximately 30% of women receive a suboptimal or poor aesthetic outcome; however there is currently no standardised method of identifying these women.The PICTURE project aims to address these…

Patient information combined for local therapy outcome assessment in bresast cancer.

The PICTURE project aims to address these issues by providing objective tools, tailored to the individual patient, to predict the aesthetic outcome of local treatment. Using a combination of 3D photography and routinely acquired radiological images…

Imaging the effect of HSP90 inhibitor AUY922 on VEGF by means of 89Zr-bevacizumab PET. A side study to the phase I-II study with AUY922 in adult patients with advanced solid malignancies, or either HER2 or ER positive locally advanced or metastatic breast cancer: protocol CAUY922A2101.

To evaluate the effect of HSP90 inhibition by AUY922 on VEGF by means of 89Zr-bevacizumab PET. Primary endpoint: measurement of decreased VEGF compared to baseline. A decline is defined as a decrease of at least 30% in mean Standardized Uptake Value…

Imaging the effect of HSP90 inhibitor AUY922 on HER2 expression by means of 89Zr-trastuzumab PET. A side study to the phase I-II study with AUY922 in either HER2 or ER positive locally advanced or metastatic breast cancer: protocol CAUY922A2101.

To show the effect of the HSP90 inhibitor AUY922 on HER2 expression by means of 89Zr-trastuzumab PET scanning. Primary endpoint: measurement of decreased HER2 expression compared to baseline. A decline is defined as a decrease of at least 30% in…

Longterm psychological riskprofiles in women at risk for hereditary breast cancer adhering to surveillance or opting for prophylactic mastectomy

To identify the determinants of psychological vulnerability through time (for the development of the prognostic risk profiles)

Clinical Performance Study Plan for Ki-67 IHC MIB-1 pharmDx (Dako Omnis) on Early Breast Cancer Specimens used to identify subjects for enrolment in AstraZeneca*s Phase III CAMBRIA-1 trial (D8531C00002)

This clinical performance study will evaluate the effectiveness of the Ki 67 IHC MIB-1 pharmDx (Dako Omnis) to identify estrogen receptor (ER)+/human epidermal growth factor receptor 2 (HER2)- early breast cancer patients whose tumours score Ki-67…